您搜索了: cladribine (英语 - 马耳他语)

cladribine /lamivudine
zidovudine /lamivudine

cladribine is a cytostatic agent.
cladribine hi sustanza ċitostatika.

each ml solution contains 2 mg cladribine.
kull millilitru ta’ soluzzjoni fih 2 mg ta’ cladribine.

cladribine is eliminated mainly by the kidneys.
clabridine huwa prinċipalment imneħħi mill-kliewi.

litak 2 mg/ml solution for injection cladribine
litak 2 mg/ ml soluzzjoni għall-injezzjoni cladribine

each vial contains 10 mg cladribine in 5 ml solution.
kull kunjett fih 10 mg ta’ cladribine f’soluzzjoni ta’ 5 ml.

each vial contains 10 mg of cladribine in 5 ml of solution.
kull kunjett fih 10 mg ta’ cladribine f’5 ml ta’ soluzzjoni.

cladribine is a purine nucleoside analogue acting as an antimetabolite.
cladribine, hu analogu nukleòside tal-purina li jaġixxi bħala anti-metabolu.

cladribine causes serious birth defects when administered during pregnancy.
cladribine jikkawża difetti serji tat-twelid meta mogħti waqt it-tqala.

cladribine is incorporated into dna strands and inhibits dna synthesis and repair.
clabridine jkun inkorporat fl-istrands tad-dna u jinibixxi s-sinteżi u t-tiswija tad-dna.

some clinical findings also support a possible interaction between lamivudine and cladribine
Ċerti sejbiet kliniċi ukoll juru l-possibiltà ta’ interazzjoni bejn lamivudine u cladribine

intracellular concentration of cladribine exceeds its plasma concentration by 128 to 375 times.
il-konċentrazzjoni intraċellulari ta’ cladribine tgħaddi l-konċentrazzjoni tagħha fil-plażma b’128 sa 375 darba.

no cytotoxic effect of cladribine could be observed in cell lines of solid tumours.
l-ebda effett ċitotossiku ta’ cladribine ma seta’ jkun osservat f’razzez ta’ ċelluli ta’ tumuri solidi.

cladribine is a cytotoxic medicinal product, which is mutagenic to cultured mammalian cells.
clabridine huwa prodott mediċinali ċitotossiku, li hu mutaġeniku fuq ċelluli mammiferi kultivati.

the combination of lamivudine with cladribine is not recommended (see section 4.5).
it-taħlita ta’ lamivudine ma’ cladribine mhux rakkomandata.

animal studies and in vitro studies with human cell lines demonstrated the teratogenicity and mutagenicity of cladribine.
studji fuq annimali u studji in vitro fuq iċ-ċelluli tal-bniedem urew it-teratoġeniċità u l-mutaġeniċità ta’ cladribine.

because cladribine has been used for a number of years, the company presented data from the published literature.
billi cladribine ilu jintuża għal għadd ta’ snin, il-kumpanija ppreżentat dejta mil-letteratura ppubblikata.

unlike other nucleoside analogues, cladribine is toxic in rapidly proliferating cells as well as in resting cells.
b’kuntrast ma’ analogi nukleòsidi oħra, cladribine huwa tossiku f’ċelluli li jkunu qed jitkattru b’mod mgħaġġel kif ukoll f’ċelluli li qed jistrieħu.

in case of pregnancy during therapy with cladribine, the woman should be informed about the potential hazard to the foetus.
f’każ ta’ tqala waqt terapija bi cladribine, il-mara għandha tkun infurmata dwar il-periklu potenzjali għall-fetu.

due to a potential increase of haematological toxicity and bone marrow suppression, cladribine must not be used concomitantly with other myelosuppressive medicinal products.
minħabba l-possibbiltà potenzjali ta’ żieda fit-tossiċità ematoloġika u fit-trażżin tal-mudullun, cladribine ma jridx jintuża flimkien ma’ prodotti mediċinali oħra li jrażżnu l-funzjoni tal-mudullun.